Imugene Limited

ASX:IMU ISIN:AU000000IMU9

Imugene Limited ASX IMUImugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

 
    
        

Ver en Otros Idiomas

Noticias

Reporte del Mercado Australiano del 16 de Septiembre del 2010: Conquest Mining Limited (ASX:CQT) Acepta un Contrato de Suministro de Insumo de Oro-Plata-Cobre con Shandong Guoda Gold

🕔9/16/2010 1:30:08 PM 12229

Reporte del Mercado Australiano del 16 de Septiembre del 2010 incluye; Conquest Mining Limited (ASX:CQT) acepta un contrato de suministro de insumo para la venta de oro-plata-cobre concentrado para su depósito V2 en Mt Carlton, Heemskirk Consolidated Limited (ASX:HSK) ha anunciado la firma de un acuerdo con Conquest Mining Limited (ASX:CQT) Imugene Limited (ASX:IMU) anunció hoy que ha terminado con éxito un segundo ensayo de su vacuna del Síndrome Reproductivo y Respiratorio Porcino (PRRS por sus siglás en inglés) y Synthesis Energy Systems Inc. (NASDAQ:SYMX) y Coalworks Limited (ASX:CWK) hicieron hoy una presentación conjunta titulada "Producción de Combustibles Líquidos de Carbón de Oaklands que Utiliza Tecnología U-GAS (R) y MTG"

Leer el artículo completo
###

78,654 Visitas al Perfil de la Empresa

  • Número de visitas: (Últimos 7 Días: 14) (Últimos 30 Días: 67) (Desde su Publicación: 7656) 

Datos de la Empresa

    Sede
  • Suite 1, 1233 High Street
    Armadale, VIC 3143
    Australia
  • Teléfono
  • +61-3-9824-5254 
  • Fax
  • +61-3-9822-7735 
  • Principal Sector
  • Health & Pharm 
  • Principal Industria
  • Biotechnology 
  • Página Principal
  • www.imugene.com

Más Resultados de Noticias

  • 2024/09/30: Change of Director's Interest Notice - PH*
  • 2024/09/18: Imugene Receives Orphan Drug Designation for VAXINIA*
  • 2024/09/11: Appendix 2A*
  • 2024/09/09: Imugene Corporate Presentation*
  • 2024/09/04: Cleansing Notice*
  • 2024/09/04: Imugene Azer-cel Webinar Presentation*
  • 2024/09/03: Imugene Webinar - Azer-cel Trial Update*
  • 2024/09/02: Three Complete Responses in Azer-Cel Phase 1b Trial*
  • 2024/08/30: Imugene ESG Report 2024*
  • 2024/08/30: Corporate Governance Statement 2024 and Appendix 4G*
*refer to company website

Social Media